News Related to Finerenone

Related coverage linked through entity extraction aliases.

Finerenone Shows Kidney Benefit in Non-Diabetic CKD in Phase III FIND-CKD Trial

Mar 19, 2026

Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.

Finerenone Reduces Albuminuria in Type 1 Diabetes; SGLT2 Inhibitors Outperform GLP-1s for Kidneys

Mar 05, 2026

Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.